|
ZNF619 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 8.56949955441166E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.92030003010046E-09 |
| Normal-vs-Stage2 |
9.69050000021454E-07 |
| Normal-vs-Stage3 |
6.85209999851111E-10 |
| Normal-vs-Stage4 |
1.57780000176189E-09 |
| Stage1-vs-Stage2 |
6.252000E-01 |
| Stage1-vs-Stage3 |
4.041200E-01 |
| Stage1-vs-Stage4 |
3.282800E-01 |
| Stage2-vs-Stage3 |
3.219200E-01 |
| Stage2-vs-Stage4 |
2.653200E-01 |
| Stage3-vs-Stage4 |
7.465800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.50980039371041E-10 |
| Normal-vs-AfricanAmerican |
2.35499999999833E-05 |
| Normal-vs-Asian |
3.30530000003382E-06 |
| Caucasian-vs-AfricanAmerican |
1.979400E-01 |
| Caucasian-vs-Asian |
1.792230E-01 |
| AfricanAmerican-vs-Asian |
8.344200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.07379693814869E-11 |
| Normal-vs-Female |
3.65899999188457E-09 |
| Male-vs-Female |
2.427800E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.25569996015196E-09 |
| Normal-vs-Age(41-60Yrs) |
1.73780001500035E-09 |
| Normal-vs-Age(61-80Yrs) |
3.55420004538587E-09 |
| Normal-vs-Age(81-100Yrs) |
4.378800E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.666800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.573600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.566600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.799000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.507000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.959400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.762600E-01 |
| Classical-VS-Follicular |
1.734210E-01 |
| Classical-VS-Other |
1.310160E-01 |
| Classical-VS-Normal |
1.25319999932927E-08 |
| Tall-VS-Follicular |
8.630600E-01 |
| Tall-VS-Other |
3.076600E-01 |
| Tall-VS-Normal |
1.27989999709754E-08 |
| Follicular-VS-Other |
3.262200E-01 |
| Follicular-VS-Normal |
2.26240004508327E-09 |
| Other-VS-Normal |
7.629100E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.69850000730776E-09 |
| Normal-vs-N1 |
5.72999980796851E-10 |
| N0-vs-N1 |
1.923610E-01 |
|
|
